Am Fam Physician. 2005 Oct 1;72(7):1172-1174.
to the editor: I read with interest the article1 by McConaghy and Smith in American Family Physician, on the outpatient treatment of systolic heart failure. I want to clarify two points. First, the authors correctly note that the Randomized Aldactone Evaluation Study (RALES) showed reductions in mortality and hospitalization in patients with congestive heart failure who received spironolactone (Aldactone). However, publication of these findings was associated with an abrupt increase in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality.2 Other studies3,4 have reported much higher rates of drug discontinuation because of hyperkalemia than those reported in RALES, particularly in the presence of angiotensin-converting enzyme inhibitors. These differences highlight the challenge of translating findings from controlled trials into practice, and suggest the need for intensive monitoring of serum potassium levels in patients receiving spironolactone for this purpose.
Second, the authors correctly note that the first Vasodilator-Heart Failure Trial (V-HeFT I) showed no improvement in overall mortality in patients given a combination of hydralazine (Sorbitrate) plus isosorbide (Apresoline) dinitrate compared with those treated with enalapril (Vasotec). However, a subanalysis5 showed benefit for blacks, and the recent African-American Heart Failure Trial (A-HeFT),6 involving only blacks, showed a 43 percent reduction in all-cause mortality among patients receiving hydralazine plus isosorbide dinitrate in addition to standard therapy. Both drugs are available generically at modest cost.
1. McConaghy JR, Smith SR. Outpatient treatment of systolic heart failure. Am Fam Physician. 2004;70:2157–64.
2. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.
3. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003;18:1814–9.
4. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure—a cautionary message. Br J Clin Pharmacol. 2004;58:554–7.
5. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178–87.
6. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.
editor’s note: This letter was sent to the authors of “Outpatient Treatment of Systolic Heart Failure,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions